Figure 5
From: Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment
Simulation of the effect of drugs on human ventricular action potential. (A) The virtual AP from virtual human ventricular myocytes harboring WT SCN5A was compared with that from A1656D mutant harboring cells at 1 Hz. AP was significantly elongated in the A1656D mutant after 60 sec of stimulation at 1 Hz. B-D. Simulated effects of 10 μM mexiletine (B), 1 μM flecainide (C), and 50 μM ranolazine (D) on the AP of virtual human ventricular myocytes with A1656D mutation.
